tebipenem has been researched along with Diarrhea* in 2 studies
1 trial(s) available for tebipenem and Diarrhea
Article | Year |
---|---|
Safety, Pharmacokinetics, and Food Effect of Tebipenem Pivoxil Hydrobromide after Single and Multiple Ascending Oral Doses in Healthy Adult Subjects.
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr, formerly SPR994) is an orally available prodrug of tebipenem, a carbapenem with activity versus multidrug-resistant (MDR) Gram-negative pathogens, including quinolone-resistant and extended-spectrum-β-lactamase-producing Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Carbapenems; Diarrhea; Fasting; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Prodrugs | 2019 |
1 other study(ies) available for tebipenem and Diarrhea
Article | Year |
---|---|
The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant
Diarrhoea remains one of the leading causes of childhood mortality globally. Recent epidemiological studies conducted in low-middle income countries (LMICs) identified. Aiming to identify alternative antimicrobial chemicals with activity against antimicrobial resistant. We identified several known antimicrobial compound classes with antibacterial activity against. Our data highlight the emerging antimicrobial resistance crisis and shows that Tebipenem pivoxil (licenced for paediatric respiratory tract infections in Japan) should be accelerated into human trials and could be repurposed as an effective treatment for severe diarrhoea caused by MDR. Tres Cantos Open Lab Foundation (projects TC239 and TC246), the Bill and Melinda Gates Foundation (grant OPP1172483) and Wellcome (215515/Z/19/Z). Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Child; Communicable Diseases; Diarrhea; Drug Repositioning; Humans; Mice; Shigella; Swine | 2022 |